Immunosuppressive agents: recent developments in molecular action and clinical application.

[1]  M. Schreier,et al.  SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. , 1997, Transplantation.

[2]  T. Meerloo,et al.  SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. , 1997, Transplantation.

[3]  J. Helderman,et al.  The evolution and future of immunosuppression in renal transplantation. , 1997, Seminars in nephrology.

[4]  A. Chong,et al.  In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. , 1997, Journal of immunology.

[5]  R. Elder,et al.  The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. , 1997, Journal of immunology.

[6]  P. Linsley,et al.  Analysis of the B7 costimulatory pathway in allograft rejection. , 1997, Transplantation.

[7]  R. Morris,et al.  Leflunomide and malononitrilamides. , 1997, The American journal of the medical sciences.

[8]  P. Halloran,et al.  Immunosuppressive agents in clinical trials in transplantation. , 1997, The American journal of the medical sciences.

[9]  M. Carrier,et al.  Comparison of Neoral and Sandimmune cyclosporine for induction of immunosuppression after heart transplantation. , 1997, The Canadian journal of cardiology.

[10]  A. Tsaroucha,et al.  Mycophenolate mofetil rescue therapy in liver transplant recipients. , 1997, Transplantation proceedings.

[11]  B. Kahan.  Sirolimus: a new agent for clinical renal transplantation. , 1997, Transplantation proceedings.

[12]  D. Zarembski,et al.  Mycophenolate mofetil: a unique immunosuppressive agent. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[13]  M. First.  An update on new immunosuppressive drugs undergoing preclinical and clinical trials: potential applications in organ transplantation. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  R. Stratta.  Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. The FK/MMF Multi-Center Study Group. , 1997, Transplantation proceedings.

[15]  D. Rush,et al.  A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. , 1996, Transplantation.

[16]  P. Kao,et al.  A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. , 1996, Transplantation proceedings.

[17]  S. E. Hughes,et al.  New Immunosuppressive Drugs in Organ Transplantation , 1996, Journal of clinical pharmacology.

[18]  P. Reinke,et al.  Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. , 1996, International journal of clinical pharmacology and therapeutics.

[19]  R. Morris,et al.  Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. , 1996, Current opinion in immunology.

[20]  James M. Wilson,et al.  CD40 Ligand-Dependent T Cell Activation: Requirement of B7-CD28 Signaling Through CD40 , 1996, Science.

[21]  R. Wiesner,et al.  A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. , 1996, Transplantation.

[22]  H. Gritsch,et al.  Tacrolimus rescue therapy for renal transplant rejection. , 1996, Transplantation proceedings.

[23]  H. Amemiya.  15-Deoxyspergualin: a newly developed immunosuppressive agent and its mechanism of action and clinical effect: a review. Japan Collaborative Transplant Study Group for NKT-01. , 1996, Artificial organs.

[24]  H. Bose,,et al.  Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy. , 1996, The Journal of clinical investigation.

[25]  P. Linsley,et al.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.

[26]  G. Tydén,et al.  A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. , 1996, Transplantation proceedings.

[27]  S. Nadler,et al.  Deoxyspergualin: mechanism of action and pharmacokinetics. , 1996, Transplantation proceedings.

[28]  Molnar Kl.  Mechanism of action of rapamycin (Sirolimus, Rapamune). , 1996 .

[29]  A. Matas,et al.  A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. , 1996, Transplantation proceedings.

[30]  P. Halloran,et al.  The functional consequences of partial calcineurin inhibition in human peripheral blood mononuclear leucocytes. , 1996, Transplant immunology.

[31]  A. Chong,et al.  Regulation of B cell function by the immunosuppressive agent leflunomide. , 1996, Transplantation.

[32]  A. Allison,et al.  Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). , 1996, Clinical transplantation.

[33]  Jack Parker Davis,et al.  The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. , 1996, Biochemistry.

[34]  F. Dumont,et al.  Mechanism of action of the immunosuppressant rapamycin. , 1995, Life sciences.

[35]  H. Simmonds,et al.  Importance of Ribonucleotide Availability to Proliferating T-lymphocytes from Healthy Humans , 1995, The Journal of Biological Chemistry.

[36]  J. Slaton,et al.  Potential Applications of Therapeutic Drug Monitoring of Sirolimus Immunosuppression in Clinical Renal Transplantation , 1995, Therapeutic drug monitoring.

[37]  P. Morand,et al.  Dihydroorotate Dehydrogenase Is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory Compound (*) , 1995, The Journal of Biological Chemistry.

[38]  L. Lou,et al.  Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. , 1995, Biochemical pharmacology.

[39]  Sollinger Hw.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995 .

[40]  P. Halloran,et al.  Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. , 1995, Transplantation.

[41]  P Fauchald,et al.  PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION , 1995 .

[42]  I. Marino,et al.  Comparative evaluation of tacrolimus (Fk506) and cyclosporin a as immunosuppressive agents , 1995 .

[43]  H. A. Lee,et al.  Mizoribine as an alternative to azathioprine in triple therapy immunosuppressant regimens in cadaveric renal transplantation: two successive studies. , 1995, Transplantation proceedings.

[44]  R. Morris,et al.  Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury. , 1995, Transplantation proceedings.

[45]  S. Takahara,et al.  Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group. , 1995, Transplantation proceedings.

[46]  B D Kahan,et al.  The Synergistic Effects Of Cyclosporine, Sirolimus, And Brequinar On Heart Allograft Survival In Mice , 1995, Transplantation.

[47]  J. Kupiec-Weglinski.  New Immunosuppressive Modalities and Anti-Rejection Approaches in Organ Transplantation , 1994 .

[48]  D. Neuberg,et al.  Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. , 1994, Blood.

[49]  T. Starzl,et al.  FK506 “RESCUE” FOR RESISTANT REJECTION OF RENAL ALLOGRAFTS UNDER PRIMARY CYCLOSPORINE IMMUNOSUPPRESSION1 , 1994, Transplantation.

[50]  K. Yasumoto,et al.  The interleukin-8 AP-1 and kappa B-like sites are genetic end targets of FK506-sensitive pathway accompanied by calcium mobilization. , 1994, The Journal of biological chemistry.

[51]  T. Starzl,et al.  New Immunosuppressive Drugs: Mechanistic Insights and Potential Therapeutic Advances , 1993, Immunological reviews.

[52]  A. Allison,et al.  Mechanisms of Action of Mycophenolic Acid , 1993, Annals of the New York Academy of Sciences.

[53]  P. Linsley,et al.  Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion , 1993, The Journal of experimental medicine.

[54]  H. A. Lee,et al.  Mizoribine as an alternative to azathioprine in triple-therapy immunosuppressant regimens in cadaveric renal transplantation. , 1993, Transplantation proceedings.

[55]  A. Allison,et al.  Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. , 1993, Transplantation proceedings.

[56]  C. Groth.  Deoxyspergualin in Allogeneic Kidney and Xenogeneic Islet Transplantation: Early Clinical Trials , 1993, Annals of the New York Academy of Sciences.

[57]  B. Julian,et al.  Experience with Mycophenolate Mofetil (RS61443) in Renal Transplantation at a Single Center , 1993, Annals of surgery.

[58]  H. Amemiya,et al.  Establishment of rejection therapy with deoxyspergualin by multicentral controlled clinical studies in renal recipients. , 1993, Transplantation proceedings.

[59]  P. Huie,et al.  Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. , 1993, Transplantation proceedings.

[60]  J. Wu,et al.  Rapamycin's long-term effects on humoral and cellular immune responses in the rat. , 1993, Transplantation proceedings.

[61]  J. Najarian,et al.  Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin , 1993, The Lancet.

[62]  S. Nadler,et al.  Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. , 1992, Science.

[63]  G. Klintmalm,et al.  RS‐61443 (Mycophenolate Mofetil) A Multicenter Study for Refractory Kidney Transplant Rejection , 1992, Annals of surgery.

[64]  J. Avruch,et al.  Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. , 1992, Science.

[65]  G. Crabtree,et al.  Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases , 1992, Cell.

[66]  R. Morris,et al.  Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease , 1991, The Lancet.

[67]  B. Kahan,et al.  Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. , 1991, Transplantation.

[68]  F. Reinholt,et al.  Deoxyspergualin for liver graft rejection , 1990, The Lancet.

[69]  J. Johnston,et al.  Kidney transplantation under FK 506. , 1990, JAMA.

[70]  W. Ritschel,et al.  Improvement of peroral absorption of cyclosporine A by microemulsions. , 1990, Methods and findings in experimental and clinical pharmacology.

[71]  T. Kusumi,et al.  Dual inhibitory effect of bredinin , 1989, Cell biochemistry and function.

[72]  F. Abe,et al.  Blastogenic responses and the release of interleukins 1 and 2 by spleen cells obtained from rat skin allograft recipients administered with 15-deoxyspergualin. , 1987, The Journal of antibiotics.

[73]  R. Venkataramanan,et al.  Cyclosporine Concentration Determinations for Monitoring and Pharmacokinetic Studies , 1986, Journal of clinical pharmacology.

[74]  S. Takahara,et al.  THE IMMUNOSUPPRESSIVE MODE OF ACTION OF MIZORIBINE , 1984, Transplantation.

[75]  M. Tsuji,et al.  Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells. , 1983, Biochemical pharmacology.

[76]  T. Takeuchi,et al.  Structure of an antitumor antibiotic, spergualin. , 1981, The Journal of antibiotics.

[77]  W. L. Sumner.  Science and Life in the World , 1947, Nature.

[78]  T. Starzl,et al.  Immunosuppressive drugs : developments in anti-rejection therapy , 1994 .

[79]  G. Klintmalm,et al.  RS-61443 for treatment-resistant human liver rejection. , 1993, Transplantation proceedings.

[80]  R. Morris.  Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides , 1992 .

[81]  R. Bartlett.  Immunopharmacological profile of HWA 486, a novel isoxazol derivative--II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone, or cyclosporin A. , 1986, International journal of immunopharmacology.

[82]  P. Kandela.  South Africa: medical care of detainees. , 1985, Lancet.